MedTrace Logo

Genetic and Dietary Predictors of Anti-platelet Response

NCT04456608 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2023-12-15

No results posted yet for this study

Summary

This study will investigate differences in platelet aggregation under basal and aspirin-treated conditions in American Indian and Alaska Native people who have extreme levels (low and high) of n-3 polyunsaturated fatty acids (n-3 PUFAs, EPA and DHA) in red blood cell membranes. The study will also determine whether or not platelet aggregation under the different conditions is modified by CYP4A11, CYP4F2, CYP4F11, PEAR1, and ACTN1 gene variation.

Conditions

  • Platelet Function

Interventions

DRUG

Aspirin

Low and high n-3 PUFA participants will receive 81-mg aspirin once a day, for 6 days.

Sponsors & Collaborators

  • Southcentral Foundation

    collaborator OTHER

  • University of Montana

    collaborator OTHER

  • Oregon Health and Science University

    collaborator OTHER

  • National Institute of General Medical Sciences (NIGMS)

    collaborator NIH

  • University of Washington

    lead OTHER

Principal Investigators

  • Kenneth E Thummel, Ph.D. · University of Washington

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-01
Primary Completion
2023-07-31
Completion
2023-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04456608 on ClinicalTrials.gov